Characterization And In Vivo Efficacy Of Conamax-Derived Antibody Drug Conjugates In Preclinical Cancer Models.

Abstract

Treatments for cancer have advanced significantly over the last fifty years, and in addition to conventional chemotherapy, new treatments include radiation therapy, small-molecule-based targeted therapies, and monoclonal antibodies (mAbs). Despite the fact that these medications have significantly improved the prognosis for cancer patients, their off-target cytotoxicity usually causes detrimental side effects. An antibody-drug conjugate (ADC) combines the potent cytotoxic effects of chemotherapy medications with the specificity of monoclonal antibodies (mAbs) to provide a potential replacement. An ADC consists of three main components: an antibody, a linker, and a cytotoxic payload. The cancer cells are killed by the cytotoxic payload, specific antigens on the cancer cells are targeted by the antibody, and the linker controls the release of the medicine. This targeted approach aims to increase treatment effectiveness while lowering systemic toxicity. Currently, the FDA has authorised nine ADCs, and several more are undergoing clinical development. Recent advancements in ADC technology have improved target selection, linker chemistry, and payload efficacy. These innovations have also raised the therapeutic index and expanded the range of cancers that may be treated. Employing characterisation techniques such as mass spectrometry and chromatography is crucial in ensuring the stability, drug loading, and efficacy of ADC. As ADC technology advances, it has the potential to dramatically change the way cancer is treated by providing safer and more efficient therapy options.